Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 3/20 | 0.39 |
| ▸ | CNR1 | P21554 | 2/20 | 0.39 |
| ▸ | SRC | P12931 | 3/20 | 0.38 |
| ▸ | FLT3 | P36888 | 3/20 | 0.38 |
| ▸ | FYN | P06241 | 2/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 10/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | ABHD12 | Q8N2K0 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21552937 | 0.89 | ALDH1A1 (0.43) | CNR2CNR1SRCFLT3FYN | |
| SCHEMBL21552841 | 0.86 | HDAC6 (0.48) | SRCFLT3FYNHDAC6SOS1 | |
| SCHEMBL21564669 | 0.83 | SRC (0.39) | CNR2CNR1SRCFLT3FYN | |
| SCHEMBL21553020 | 0.82 | L3MBTL1 (0.44) | CNR2CNR1HDAC6FAAHABHD12 | |
| SCHEMBL21552820 | 0.81 | ALDH1A1 (0.35) | CNR2CNR1SRCFLT3FYN | |
| SCHEMBL21564668 | 0.81 | SRC (0.44) | CNR2CNR1SRCFLT3FYN | |
| SCHEMBL21552886 | 0.80 | ABL1 (0.43) | CNR2CNR1SRCFLT3FYN | |
| SCHEMBL21552912 | 0.76 | MAPT (0.47) | CNR2CNR1FAAHABHD12MAPT | |
| SCHEMBL21553001 | 0.75 | SRC (0.33) | SRCFLT3FYNHDAC6SOS1 | |
| SCHEMBL21564673 | 0.73 | CYP11B1 (0.42) | SRCFLT3FYNHDAC6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3790867-B1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES INC (US) | 2024-03-27 | — | — | EP | disclosed |
| US-11932629-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| US-20230250090-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES INC (US) | 2023-08-10 | — | — | US | disclosed |
| US-11578059-B2 | KDM1A inhibitors for the treatment of disease | Imago Biosciences. Inc. (US) | 2023-02-14 | — | — | US | disclosed |
| US-20210115023-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. | 2021-04-22 | — | — | US | disclosed |
| EP-3790867-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | Imago Biosciences Inc. (US) | 2021-03-17 | — | — | EP | disclosed |
| WO-2019217972-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. (US) | 2019-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11932629-B2 | KDM1A inhibitors for the treatment of disease | KDM1B, KDM1A, KDM2A | CNR2 4361/4885CNR1 4072/4885SRC 2429/4885 |
| US-20230250090-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | KDM1B, KDM1A, KDM2A | CNR2 4361/4885CNR1 4072/4885SRC 2429/4885 |
| US-20210115023-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | KDM1A, KDM1B, KDM2A | CNR2 4240/4885CNR1 3707/4885SRC 2381/4885 |
| US-11578059-B2 | KDM1A inhibitors for the treatment of disease | KDM1B, KDM1A, KDM2A | CNR2 4361/4885CNR1 4072/4885SRC 2429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.